<DOC>
	<DOCNO>NCT02623296</DOCNO>
	<brief_summary>This Phase I , randomize , double-blind , placebo-controlled , 2 period cross-over , drug-drug interaction study evaluate effect multiple oral dos GLPG1205 placebo ( daily Day 1 Day 12 ) single dose pharmacokinetic profile cocktail CYP450 substrates administer healthy male subject . The cocktail CYP450 substrates consist 10 mg warfarin ( CYP2C9 substrate ) , 20 mg omeprazole ( CYP2C19 substrate ) 100 mg caffeine ( CYP1A2 substrate ) . Fourteen healthy male subject receive two treatment period Day 1 Day 12 daily dose GLPG1205 placebo . On Day 13 , single dose cocktail CYP450 substrates co-administered either GLPG1205 placebo . The two treatment period separate wash-out period least 28 day . Also , safety tolerability multiple oral dos GLPG1205 administer without cocktail CYP450 substrates healthy male subject evaluate .</brief_summary>
	<brief_title>A Drug-drug Interaction Study Between GLPG1205 Cocktail CYP450 Substrates Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>healthy male , age 1850 year BMI 1830 kg/m2 Poor moderate metabolizer CYP2C9 CYP2C19 determine genotyping Having contraindication indicate respective Summary Product Characteristics ( Package Leaflets ) warfarin , omeprazole caffeine Intake nutraceuticals within 3 week prior dose within 6 time elimination half life Intake enzyme induce enzyme inhibit drug within 3 month prior dose Intake vitamin K within 3 week prior dose Any condition might interfere procedure test study Drug alcohol abuse Smoking</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>